<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232280</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1647-P202</org_study_id>
    <nct_id>NCT04232280</nct_id>
  </id_info>
  <brief_title>Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults</brief_title>
  <official_title>A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647&#xD;
      cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years&#xD;
      of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      mRNA-1647-P202 is a 2-part study. Part 1 of the study evaluates the safety and immunogenicity&#xD;
      of low, medium, and high dose levels of mRNA-1647 vaccine or placebo, administered on a 0, 2,&#xD;
      6-month schedule in healthy CMV-seronegative and CMV-seropositive males and females, 18 to 40&#xD;
      years of age. A planned interim analysis of safety and immunogenicity through Month 3 (1&#xD;
      month after the second dose) of Part 1 of the study informed the selection of the middle dose&#xD;
      level for further development. Part 2 of the study is designed to further evaluate the safety&#xD;
      and immunogenicity of the middle dose level of mRNA-1647 vaccine or placebo on a 0, 2,&#xD;
      6-month schedule in approximately 200 healthy participants 18 to 40 years of age, comprised&#xD;
      of CMV-seronegative and CMV-seropositive female population, which includes the target&#xD;
      population for the pivotal Phase 3 efficacy trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Observer-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Solicited Local and Systemic Adverse Reactions (ARs)</measure>
    <time_frame>Up to Day 175 (7 days following last dose administration)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Up to Day 196 (28 days following last dose administration)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Medically-Attended Adverse Events (MAAEs)</measure>
    <time_frame>Up to Day 336 (6 months following last dose administration)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 504 (1 year following last dose administration)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies Against Epithelial Cell Infection and Against Fibroblast Infection</measure>
    <time_frame>Baseline, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases in Neutralizing Antibodies (nAb) over Baseline Against Epithelial Cell Infection and Against Fibroblast Infection</measure>
    <time_frame>Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, and Day 504</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in GMT of Anti-Glycoprotein B (gB) Specific Immunoglobulin G (IgG) and Anti-Pentamer Specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) of Post-Baseline/Baseline Titers</measure>
    <time_frame>Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Associated GMR of Anti-gB Specific IgG and Anti-Pentamer Specific IgG as Measured by ELISA of Post-Baseline/Baseline Titers</measure>
    <time_frame>Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in GMT of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group</measure>
    <time_frame>Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in GMR of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group</measure>
    <time_frame>Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases over Baseline of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection</measure>
    <time_frame>Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, and Day 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in GMT of Antigen-Specific IgG (ELISA) at each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups</measure>
    <time_frame>Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in GMR of Antigen-Specific IgG (ELISA) at each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups</measure>
    <time_frame>Baseline, Day 1, Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>mRNA-1647 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mRNA-1647 vaccine at the Low Dose by intramuscular (IM) injection on Day 1, Day 56, and Day 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA-1647 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mRNA-1647 vaccine at the Medium Dose by IM injection on Day 1, Day 56, and Day 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA-1647 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mRNA-1647 vaccine at the High Dose by IM injection on Day 1, Day 56, and Day 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to the mRNA-1647 vaccine dose by IM injection on Day 1, Day 56, and Day 168.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1647</intervention_name>
    <description>Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration</description>
    <arm_group_label>mRNA-1647 High Dose</arm_group_label>
    <arm_group_label>mRNA-1647 Low Dose</arm_group_label>
    <arm_group_label>mRNA-1647 Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride (normal saline) injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18-40 years of age (Part 1); Female 18-40 years of age (Part 2)&#xD;
&#xD;
          -  Understands and agrees to comply with the trial procedures and provides written&#xD;
             informed consent&#xD;
&#xD;
          -  According to the assessment of the Investigator, is in good general health and is&#xD;
             capable of complying with trial procedures&#xD;
&#xD;
          -  Body mass index (BMI) 18-35 kilograms/meter (kg/m^2)&#xD;
&#xD;
          -  Female participants must either be of non-childbearing potential or use acceptable&#xD;
             methods of contraception from at least 28 days prior to the first vaccination and&#xD;
             through 3 months following last vaccination and is not breastfeeding.&#xD;
&#xD;
          -  Male participants must agree to practice adequate contraception from the time of the&#xD;
             first vaccination and through 3 months after the last vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acutely ill or febrile on the day of the first vaccination&#xD;
&#xD;
          -  Prior receipt of any CMV vaccine&#xD;
&#xD;
          -  Abnormal screening safety laboratory test results&#xD;
&#xD;
          -  Diagnosis or condition that, in the judgment of Investigator, is clinically unstable&#xD;
             or may affect participant safety, assessment of safety endpoints, assessment of immune&#xD;
             response, or adherence to trial procedures&#xD;
&#xD;
          -  Has received or plans to receive a vaccine ≤28 days prior to the first vaccination or&#xD;
             plans to receive a non-study vaccine within 28 days prior to or after any study&#xD;
             vaccination, except for any licensed influenza vaccine which can be administered &gt;14&#xD;
             days before or after any study vaccination. COVID-19 vaccines (regardless of&#xD;
             manufacturer) may be administered &gt;7 days but preferably &gt;14 days before or after any&#xD;
             study vaccination, with the intention of prioritizing COVID-19 vaccination over all&#xD;
             other considerations.&#xD;
&#xD;
          -  Prior receipt of chronic systemic immunosuppressants or immune-modifying drugs&#xD;
&#xD;
          -  Receipt of intravenous immunoglobulins or plasma products within 3 months prior to the&#xD;
             day of the first study vaccination&#xD;
&#xD;
          -  Previous receipt of medications in lipid nanoparticle (LNP) formulation (Part 1&#xD;
             participants only)&#xD;
&#xD;
          -  Has donated ≥450 milliliters (mL) of blood products within 28 days of the Screening&#xD;
             visit&#xD;
&#xD;
          -  Participated in an interventional clinical trial within 28 days prior to the day of&#xD;
             enrollment&#xD;
&#xD;
          -  Is an immediate family member or household member of trial personnel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213-6523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic-South Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderna</keyword>
  <keyword>mRNA-1647</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <keyword>Cytomegalovirus Vaccine</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Cytomegalovirus Congenital</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Infection Viral</keyword>
  <keyword>DNA Virus Infections</keyword>
  <keyword>Messenger RNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

